Pulmonary hypertension and idiopathic pulmonary fibrosis: A dastardly duo

American Journal of the Medical Sciences

Volumn 346, Issue 3, 2013, Pages 221-225

  Smith, J Shaun ^a   Gorbett, Daniel ^b   Mueller, Julianne ^b   Perez, Rafael ^a   Daniels, Curt J ^b  

^a University of Louisville School of Medicine   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Idiopathic pulmonary fibrosis; Interstitial lung disease; Pulmonary hypertension

Indexed keywords

BOSENTAN; PROSTACYCLIN;

ARTERIAL OXYGEN SATURATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; GAS EXCHANGE; HEART CATHETERIZATION; HEART INDEX; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOXEMIA; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG TRANSPLANTATION; LUNG VOLUME; OVERALL SURVIVAL; OXYGEN SATURATION; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PULMONARY ARTERY; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; THORAX RADIOGRAPHY;

EID: 84883742373     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31827871dc     Document Type: Review

References (36)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-52.
3. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;183:431-40.
4. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005;128:2393-9. (Pubitemid 41507585)
5. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007;175:875-80. (Pubitemid 46684695)
6. Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008;76:288-94.
7. Yang S, Johnson C, Hoffman K, et al. Pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis when listed for lung transplantation (LT) and at LT. Proc Am Thorac Soc 2006;3:A369.
8. Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008;102:1305-10.
9. McGoon MD, Kane GC. Pulmonary hypertension: diagnosis and management. Mayo Clin Proc 2009;84:191-207.
10. Patel NM, Lederer DJ, Borczuk AC, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007;132:998-1006.
11. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004;170:360-5. (Pubitemid 39214607)
12. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007;131:657-63. (Pubitemid 46446854)
13. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-40. (Pubitemid 36801751)
14. Zisman DA, Karlamangla AS, Kawut SM, et al. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2008;133:640-5. (Pubitemid 351367371)
15. Zisman DA, Ross DJ, Belperio JA, et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007;101:2153-9. (Pubitemid 47324243)
16. Ryu JH, Krowka MJ, Pellikka PA, et al. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 2007;82:342-50. (Pubitemid 46348935)
17. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
18. Strange C, Bolster M, Mazur J, et al. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000;118:1077-82.
19. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. (Pubitemid 41653106)
20. Madden BP, Allenby M, Loke TK, et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006;44:372-6.
21. Madden BP, Sheth A, Wilde M, et al. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease? Vascul Pharmacol 2007;47:184-8. (Pubitemid 47096872)
22. Chapman TH, Wilde M, Sheth A, et al. Sildenafil therapy in secondary pulmonary hypertension: is there benefit in prolonged use? Vascul Pharmacol 2009;51:90-5.
23. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131:897-9. (Pubitemid 46446887)
24. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900. (Pubitemid 35283832)
25. Zisman DA, Schwarz, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8.
26. Jackson RM, Glassberg MK, Ramos CF, et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010;188:115-23.
27. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
28. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006;36(Suppl 3):10-5. (Pubitemid 44179776)
29. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120:1562-9. (Pubitemid 33078473)
30. Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-93. (Pubitemid 127498240)
31. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81.
32. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:92-9.
33. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160:600-7. (Pubitemid 29380679)
34. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:88-95.
35. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT). Am J Respir Crit Care Med 1998;158:335-9.
36. Fitton TP, Kosowski TR, Barreiro CJ, et al. Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005;24:1254-9. (Pubitemid 41247807)